|Day Low/High||6.94 / 7.10|
|52 Wk Low/High||4.50 / 11.69|
Dr. David B. Weiner recognized for his innovative medical and scientific research, which has been the basis for over 100 patents
Four of five study subjects in treated group show progression free survival ranging from nine to 24 months to date in phase I/IIa clinical study
Stocks closed with gains on Monday as T-Mobile led the Nasdaq amid better-than-expected earnings, while B/E Aerospace soared following announcement of its acquisition by Rockwell Collins.
Stocks stay in the green Monday as M&A and earnings reports lead the market higher, while manufacturing orders rise.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
In trading on Friday, shares of Inovio Pharmaceuticals Inc. crossed below their 200 day moving average of $8.62, changing hands as low as $8.60 per share.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the May 2017 expiration.
Popular Mechanics magazine calls Inovio's Zika prevention a completely new form of vaccination that may be the fastest vaccine ever to come to market
Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.
Inovio (INO) said on Monday that it initiated a clinical study of its preventive Zika vaccine in 160 subjects in Puerto Rico.
Inovio's second human Zika vaccine study, a placebo-controlled 160-subject trial, will test for safety, immune responses and initial evidence of efficacy
With a new Zika case now confirmed on Florida's East Coast, here's four stocks investors should consider as concerns about the virus reach an all-time high
Investors in Inovio Pharmaceuticals Inc. saw new options become available today, for the October 21st expiration.
Further enrollment to also build on safety database for Ebola and SynCon® immunotherapy technology, which has a favorable safety profile to date
Trade-Ideas LLC identified Inovio Pharmaceuticals (INO) as a weak on high relative volume candidate
Inovio (INO) reported a bigger-than-expected loss for the 2016 second quarter before Monday's market open.